SCHEMBL466865

SCHEMBL466865

CCN1CCCC1CN(C)CCc1ccc(Cl)c(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 20/20 1.00
CYP1A2 P05177 3/20 0.54
CYP2D6 P10635 3/20 0.54
TSHR P16473 3/20 0.54
TP53 P04637 2/20 0.54
CYP3A4 P08684 2/20 0.53
GRIN2D O15399 1/20 0.53
GRIN3B O60391 1/20 0.53
GRIN1 Q05586 1/20 0.53
GRIN2A Q12879 1/20 0.53
GRIN2B Q13224 1/20 0.53
GRIN2C Q14957 1/20 0.53
GRIN3A Q8TCU5 1/20 0.53
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
OPRK1 P41145 1/20 0.49
CYP2C19 P33261 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7447651 0.84 SIGMAR1 (0.72) SIGMAR1CYP1A2CYP2D6TSHRCYP3A4
SCHEMBL7442708 0.82 SIGMAR1 (1.00) SIGMAR1CYP1A2CYP2D6TSHRTP53
SCHEMBL5935208 0.77 SIGMAR1 (1.00) SIGMAR1TSHR
SCHEMBL7429031 0.77 SIGMAR1 (0.74) SIGMAR1CYP1A2CYP2D6TSHRTP53
SCHEMBL7436091 0.74 SIGMAR1 (0.58) SIGMAR1TSHROPRK1
SCHEMBL5935226 0.74 SIGMAR1 (0.93) SIGMAR1TSHR
SCHEMBL5935280 0.74 SIGMAR1 (0.80) SIGMAR1CYP1A2CYP2D6TSHRTP53
SCHEMBL5935249 0.73 SIGMAR1 (0.79) SIGMAR1CYP1A2CYP2D6TSHRTP53
SCHEMBL5935268 0.73 SIGMAR1 (0.91) SIGMAR1TSHR
SCHEMBL24688442 0.73 SIGMAR1 (0.56) SIGMAR1TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5571832-A Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-11-05 US claimed
EP-2600863-B1 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA ESTEVE LABOR DR (ES) 2018-03-28 EP disclosed
EP-2646025-B1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN ESTEVE LABOR DR (ES) 2017-03-15 EP disclosed
EP-2531191-B1 Sigma ligands for use in the prevention and/or treatment of postoperative pain ESTEVE LABOR DR (ES) 2016-03-30 EP disclosed
EP-2571501-B1 SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY ESTEVE LABOR DR (ES) 2016-03-02 EP disclosed
EP-2460519-A1 Use of sigma ligands in bone cancer pain Laboratorios Del. Dr. Esteve, S.A. (ES) 2012-06-06 EP disclosed
EP-2415471-A1 Use of sigma ligands in opioid-induced hyperalgesia Laboratorios Del. Dr. Esteve, S.A. (ES) 2012-02-08 EP disclosed
EP-2388005-A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-11-23 EP disclosed
EP-2353598-A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-08-10 EP disclosed
US-5571832-A Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-11-05 US disclosed